ObjectiveThis article aims to comprehensively retrieve and summarize the best evidence for the self-management of epilepsy in adolescents, so as to provide a reference for clinical medical staff and relevant decision makers. MethodsWe systematically searched Cochrane, Global Guidelines Collaboration (GIN), Scottish Interhospital Guidelines Network (SIGN), Joanna Briggs Institute (JBI), NICE, RANO (Nurses' Association of Ontario, Canada), UpToDate, BMJ, Medical Maitong, PubMed, International League Against Epilepsy, China National Knowledge Infrastructure, Wanfang Database and other databases and websites. All kinds of literature related to the self-management of epilepsy in adolescents were collected from the establishment of the database to April 18, 2023, including clinical decision-making, clinical guidelines,. Evidence summary, expert consensus, systematic review, etc. Four researchers were invited to evaluate the quality of the retrieved guidelines, and two researchers independently screened and evaluated the quality of the remaining literature. According to the opinions of professionals, data extraction and analysis were performed on the literature that met the inclusion criteria. ResultsA total of 9 articles were included, including 3 clinical guidelines, 3 expert consensus and 3 systematic reviews. We summarized the evidence in the literature in the following 8 aspects: Self-management initiation timing, monitoring management, psychological management, innovative self-management mode, information and support, medication management, daily life management and follow-up management. We identified 34 best pieces of evidence. ConclusionsThis article provides health care providers with the best evidence for the self-management of adolescents with epilepsy, guiding them to provide self-management education and counseling for adolescents with epilepsy through evidence-based methods, helping them to improve self-management ability, reduce seizures, reduce health services and healthcare costs, and improve quality of life.
Adenoid hypertrophy in children with epilepsy is rarely reported. This paper analyzes the clinical characteristics and incidence of adenoid hypertrophy in children with epilepsy.Methods The clinical data in children with epilepsy from December 2014 to April 2020 in Shenzhen Children's hospital were analyzed retrospectively.Results There were 449 cases diagnosed with adenoid hypertrophy (2.74%) in 16387 children with epilepsy. Among 449 cases of adenoid hypertrophy, 276 males (61.47%) and 173 females (38.53%). The age distribution was: 28 days to 1 year old, 8 cases (2%); 1-3 years old, 78 cases (17%); 3-6 years old 167 cases (37%); 6-12 years old, 153 cases (34%); 12-18 years old, 43 cases (10%). In 40 patients the IgG antibody were positive for EB capsid antigen in 25 (62.5%). In 56 cases of EB virus DNA were detected by fluorescence quantitative PCR, 25 (44.64%) positive, and 21/44 cases (47.72%) were positive by general nucleic acid detection of enteroviruses. The neutrophil reduction rate in peripheral blood was 42.19% in 673 tests, lymphocyteincreased in 292 (43.38%), platelet count increased in 307 (45.61%), abnormal in platelet hematocrit in 311 (46.21%); the mean volume of RBC was decreased in319 (47.39%) tests. The content of \begin{document}${\rm{HCO}_3^-} $\end{document} was reduced in 20/55 cases (36.36%). 25-hydroxy vitamin D was 33 (44.5%) decreased in 74 cases. The blood glucose was measured in 146 cases, 60 (41.09%) increased, total cholesterol was 31 (40.78%) increased in 76 cases, serum C peptide was 12 (29.26%) increased in 41 cases.Conclusion Adenoid hypertrophy in children with epilepsy may be related to infection, inflammation or immune disorder, which may cause nutritional, metabolic or internal environment disorders. Therefore, there is need of nursing and health education, transferring to specialized centers for diagnosis and treatment.